

Treatment of Pemphigus: A Local Experience

Pages with reference to book, From 300 To 304

Shahid Javaid Akhtar (Departments of Dermatology, Punjab Medical College, Faisalabad.)

Manzoor Ul Hasan (King Edward Medical College, Lahore.)

Abstract

A clinical study was conducted to evaluate the efficacy and safety of three currently used treatment modalities for pemphigus. Seventy-two patients of pemphigus (pemphigus vulgaris and severe cases of pemphigus vegetans, pemphigus foliaceus and pemphigus erythematosus) were divided into three groups. Forty patients were treated with prednisolone, 15 with a combination of prednisolone plus azathioprine and 17 patients with betamethasone-cyclophosphamide pulse (BC?) therapy. All patients were followed from 9 to 21 months (mean 16 months), There was no statistical difference between steroid and azathioprine-corticosteroid therapy groups in terms of time taken to achieve initial control of the disease but the frequency of relapses and the incidence of complications were higher in patients treated with corticosteroids alone ($p < 0.05$). A marginally increased susceptibility to infections was seen in patients treated with BC? therapy as compared with azathioprine-corticosteroid group ($p = 0.07$). Seventy percent patients treated with BC? therapy required additional steroids in between the monthly pulses, indicating failure of BC? as sole therapy. It was concluded that azathioprine-corticosteroid treatment of pemphigus was more effective and comparatively safer than steroid alone or BC? therapy (JPMA 48:300, 1998).

Introduction

Pemphigus is an autoimmune intraepidermal blistering disease affecting the skin and mucous membranes. It is mediated by autoantibodies directed against the keratinocyte surface antigens. Antigen-antibody interaction is responsible for detachment of epithelial cell from each other¹. Prior to the advent of corticosteroids, majority of patients with pemphigus used to die². Survival of these patients has improved since 1950 when systemic corticosteroids were introduced³. Reported deaths with generalized skin lesions became rare but side effects of steroid therapy became the major cause of mortality⁴. Because of the problem of steroid-related side effects, adjuvants like cytotoxic drugs, gold, dapsone and cyclosporin have been added to the treatment of pemphigus to attain a steroid-sparing effect. These agents, however, are not without side effects. Opinion in the literature is divided the optimum dosage of steroids and efficacy immunosuppressive agents in pemphigus⁵.

The present study was done to evaluate the efficacy and safety of three currently used treatment modalities in pemphigus. Clinical trial of this sort, simultaneously comparing three different treatment regimens, has not been reported locally.

Patients and Methods

Seventy-two pemphigus patients were divided into three treatment groups (Table I).

Table I. Profile of the patients.

Type of pemphigus	Group A	Group B	Group C
P. vulgaris	35	13	12
P. vegetans	-	1	-
P. foliaceus	5	1	4
P. erythematosus	-	-	1
Total	40	15	17

Group A had more patients than groups B and C because cytotoxic drugs were avoided in pregnant and lactating women and non-affording patients were also allocated to group A.

Diagnosis of pemphigus was established on the basis of clinical features, Tzanck smears and H/E stained skin biopsies. Clinical parameters were recorded in a specially designed proforma and the severity of pemphigus graded according to the percentage of body surface area involved as recommended by Piainphogsant and Ophaswongse⁶. Laboratory evaluation included full platelet count, ESR, fasting blood sugar, blood urea, serum creatinine, LFTs, serum electrolytes, urinalysis, complete stool examination and chest X-ray.

Group A was given glucocorticosteroids as the specific therapy. The starting dose varied from 30-120 mg/day of prednisolone, given in three divided doses, depending upon the severity and type of pemphigus (Table II).

Table II. Starting dose of prednisolone (mg/day).

Pemphigus vulgaris and vegetans	
Mild (<10% body area)	60
Moderate (10-30% body area)	60-90
Severe (>30% body area)	90-120
Pemphigus foliaceus and erythematosus	
Mild and moderate (<30% body area)	30-40
Severe (>30% body area)	40-50

First reduction of 20-25% in the initial dose of steroid and conversion to single daily morning dose were made when 80-90% of the initial lesions had healed. Subsequent reductions of smaller volume were made monthly.

Once a daily dose of 40 mg of prednisolone was achieved without loss of control over disease activity, an attempt was made to shift the patients on alternate-day steroid therapy. They were then, maintained on 40 mg of prednisolone on alternate days for 4-6 months. If they remained in clinical remission, further gradual reductions of 2.5 mg prednisolone every 2-3 weeks were made. In case of any relapse, the dose of prednisolone was escalated by 25 to 50% every one to two weeks, depending upon the rate of progression, until control was attained. Patient's clinical condition was the main parameter used to adjust the dosage of steroids.

Group B was given azathioprine (100-150 mg/day) in addition to the usual prednisolone dosages as mentioned for group A. With the control of the disease, steroids were tapered first followed by reduction in azathioprine.

Group C was placed on betamethasonecyclophosphamide pulse (BCP) therapy. Each monthly pulse consisted of 100 mg of betamethasone, dissolved in 5% dextrose, given in a drip over a period of 2-3 hours on three consecutive days. In addition, 500 mg of cyclophosphamide was added in the same drip on the first day. In between the pulses, patients were given 50 mg of cyclophosphamide orally each day. Each cyclophosphamide infusion was accompanied by vigorous oral hydration to promote frequent urination for 24 hours to protect the bladder from toxic effects.

The BCP therapy was divided into four phases. During phase I, patients continued to have pemphigus lesions. The lesions would, however, tend to heal after each monthly pulse but after a few days new lesions would appear. After a variable number of betamethasone-cyclophosphamide pulses, the relapses would start becoming milder and ultimately the patients would go into the next phase (i.e., phase II), the phase of remission while on the therapy. After the patients had remained in clinical remission for a minimum of 6 months, monthly courses of BCPs were stopped, but 50 mg cyclophosphamide was continued (phase III). After one year of phase III, oral cyclophosphamide was also withdrawn and the patients were followed for a minimum of two years (phase IV), to confirm the possibility of a complete cure.

The three treatment groups were compared with regards to the time taken for healing of lesions, frequency of relapses and incidence of treatment related complications. Patients were seen every week or two while being treated with divided daily doses of prednisolone and until the disease was clinically active. Thereafter, regular follow-ups were done once a month. At the completion of the study period, i.e., by June 30, 1993, all patients had a follow-up period of 9 to 21 months (mean 16 months). All laboratory investigations, done as base line, were repeated on each follow-up. In addition to a complete clinical examination conducted on each visit, periodic examination for systemic and cutaneous complications of therapy were carried out. The chi-squared test was used for statistical analysis. Significance was defined as $p < 0.05$.

Results

Forty patients of pemphigus (pemphigus vulgaris 35 and pemphigus foliaceus 5) were treated with glucocorticosteroids as the specific therapy (Group A). Of these, six patients were lost to follow up and eleven were non-compliant to the treatment schedules prescribed so that their status could not be evaluated for comparison. Eight patients died after a variable period of treatment, six because of uncontrolled infections, one due to adrenal insufficiency and one because of unknown cause (Table III).

Table III. Modes of death.

	Group A (n=40)	Group B (n=15)	Group C (n=17)
Infections	6	1	2
Unknown	1	0	1
Ischaemic heart disease	0	0	1
Adrenal insufficiency	1	0	0
Total	8	1	4

Initial control of the disease was achieved in 5-49 days (mean 22.7). However, nine relapses occurred in five patients while the steroids were being tapered. At the end of the study period, thirteen patients in this group were in clinical remission and were taking 15-40 mg of prednisolone on alternate days (Table IV).

Table IV. Status of the patients at the end of the study.

	Group A	Group B	Group C
Remission	13	11	10*
Death	8	1	4
Lost	6	1	3
Non-compliant	13	2	0
Total	40	15	17

*Two patients were shifted to conventional steroid therapy.

Group B consisted of 15 patients, thirteen of pemphigus vulgaris and one each of pemphigus vegetans and pemphigus foliaceus (Table V).

Table V. Systemic complications of the therapy.

	Group A (n=13)	Group B (n=11)	Group C (n=10)
Respiratory infections	10	6	9
Dyspepsia	7	3	2
Nausea	1	0	1
Obesity	11	3	0
Myopathy	3	2	2
Hyperglycemia	2	1	0
Hypertension	1	0	0
Psychosis	4	0	0
Amenorrhoea	3	2	1
Electrolyte imbalance	3	2	1
Osteoporosis	2	0	0
Cataract	1	0	0

One patient was lost to follow up and one died due to bronchopneumoma. Two patients were non-compliant with the therapy, rest of eleven patients were symptom free at their last follow up and were taking 10-30mg of prednisolone on alternate days in addition to 100-150 mg/day azathioprine (Table IV).

Table VI. Cutaneous complications of the therapy.

	Group A (n=13)	Group B (n=11)	Group C (n=10)
Pyoderma	11	8	9
Eczema herpeticum	1	2	2
Candidiasis	9	8	2
Moon face	11	4	1
Acne	7	2	1
Striae	11	3	1
Hirsutism	4	0	0
Alopecia	1	2	4
Phlebitis	1	0	0

The duration of treatment before the initial control of disease was achieved varied from 7 to 48 days (mean 21.2). In this group, two patients had three relapses while the steroids and/or azathioprine were being reduced.

Seventeen patients of pemphigus (pemphigus vulgaris 12, pemphigus foliaceus 4 and pemphigus erythematous 1) were treated with betamethasone-cyclophosphamide pulse (pemphigus vulgaris 10, pemphigus foliaceus 2) were given additional 20-30 mg of prednisolone per day for first 2-3 months as BCP therapy alone failed to control skin blistering. In this group, three patients were lost to follow up after an average period of 2.7 months. One patient died of bronchopneumonia, one due to septicemia and another because of ischaemic heart disease. One patient died at home of unknown cause.

Because of poor response to BCP therapy, two patients of pemphigus foliaceus were shifted to conventional steroid therapy after 4-5 months. Eight patients were in clinical remission at their last follow up; three were receiving BCPs, while in five patients monthly pulses had been stopped and they were taking only 50 mg cyclophosphamide daily. The duration of phase I varied from 3 to 16 months (mean 7.7 months). Once the patients went into clinical remission (phase II), they remained in remission.

Table V and VI list the treatment related complications observed in the patients who are now in clinical remission. Some patients developed more than one form of complications and/or repeated episodes of a single side-effect. However, an increase in susceptibility to infections was seen in all the treatment groups.

Discussion

Oral prednisolone was administered initially in three divided daily doses to obtain a rapid control of the disease. Daily single-dose and alternate-day corticosteroid treatment schedules do reduce the incidence of side effects⁸ but the response may be delayed^{9,10}. Once the disease process was controlled, a shift to single morning dose and then to alternate day therapy was made in order to reduce the long-term complications of corticosteroid administration. A maximum daily dose of 120 mg of prednisolone was effective in controlling skin blistering. The much higher dosage recommended by Lever⁹ was not used because of the adverse effects observed by others^{2,3,11,12}. Oral ulcerations were particularly difficult to treat and were very painful. Indeed, mucosal lesions of pemphigus respond to therapy more slowly than the skin lesions¹³.

There was statistically no significant difference between Groups A and B in terms of time taken to achieve initial control of the disease ($p=0.9$), but the frequency of relapses and incidence of treatment complications were higher in patients treated with steroids alone ($p<0.05$). Though at the end of the study period the maintenance doses of steroids in Groups A and B (15-40 and 10-30 mg on alternate days, respectively) were not much different, azathioprine allowed early reductions in prednisolone dosages in Group B. This resulted in lower cumulative prednisolone dose and hence reduced incidence of side effects in this treatment group. Group C was treated with an arbitrarily designed regimen pioneered by Pasricha¹⁴. We, however, used betamethasone instead of dexamethasone for monthly pulses. Methyl-prednisolone is the usual brand recommended for glucocorticosteroid pulse therapy¹⁵, but betamethasone was chosen because of its easy availability and cost factor.

Our results of betamethasone-cyclophosphamide pulse therapy were not as dramatic as are reported in the literature^{14,16,17}. Twelve patients (70%) required additional prednisolone in between the monthly pulses for first 2-3 months to lessen the severity of the disease. Although the dosage of additional steroids used was smaller (20-30 mg of prednisolone per day) it does indicate the failure of BCP as sole therapy in initial stages of treatment. The other and more important drawback of BCP therapy was an increase in susceptibility to infections ($p=0.07$). Nine patients developed 14 episodes of respiratory tract infections, two developed eczema herpeticum and 9 patients suffered repeated attacks of moderate to severe pyogenic cutaneous infections. But metabolic complications of steroids and cyclophosphamide induced bone marrow suppression were not observed.

Though BCP therapy is not suitable for routine management of the patients with pemphigus, it may be used in patients with the severe disease refractory to less toxic form of treatment or for those who have coexisting medical illness (e.g. hypertension, diabetes mellitus) that could be exacerbated by long-term continuous use of corticosteroids.

Multiple treatment schedules of glucocorticoids have been proposed for the management of patients with pemphigus. Lever recommended a high initial dose of 180-360 mg/day of prednisone to control the disease rapidly⁹. On the other hand, Hietanen and Salo¹⁸ and Smorle and Arazt¹⁹ have treated pemphigus patients with prednisolone in doses as low as 61.4 and 87 mg/day, respectively. Latter workers observed that patients receiving prednisolone in a dosage of 120 mg/day had lower mortality rates than those who received higher doses of steroids¹². Ratnam and associates reported that high dose prednisolone therapy did not have any long term benefit over the low dose regimen with respect to the frequency of relapse or the incidence of complications²⁰.

Though corticosteroids remain the mainstay of treatment for control of acute episodes²¹, several adjuvants have become available for overall management of a patients with pemphigus. Bystryn suggested that the remission rate of patients treated with adjuvants was only slightly better than those treated with corticosteroids alone⁵. But Pianiphongsant and Ophaswongse recommend the use of cyclophosphamide or other immunosuppressant agents like azathioprine as a standard therapy for all

types of moderate or severe pemphigus⁶. Peiying and associates also believe that combination therapy in pemphigus is more effective than steroids alone²². Our results suggest that azathioprine--corticosteroid treatment is highly effective and safe. Azathioprine exerted an impressive steroid-saving effect and this resulted in reduction of incidence of side effects (Table IV and V) and rate of relapses ($p < 0.05$). The mortality was also low with the combined azathioprine-steroid therapy, although the difference was not statistically significant ($p = 0.2$).

Many different regimens have been employed for the treatment of pemphigus patients^{2,5,18,23-26}, but the protocol advocated by Korman²¹ seems very reasonable. He recommends an initial starting dose of 40 to 60 mg/day of prednisolone for mild to moderate pemphigus and 80 to 100 mg/day for severe disease. In addition, use of immunosuppressive agents, such as cyclophosphamide or azathioprine, is advised at the outset in older patients. In young patients, the disease cannot be brought under control with a dose of prednisolone that is low enough for long-term therapy, other agents such as gold or azathioprine may be added in an attempt to decrease the steroid requirements²¹. In addition, use of topical and/or intralesional steroids can speed the resolution of individual lesions of pemphigus⁵. This modality is also useful to control superficial variety of mild pemphigus manifested by only a few lesions. Some patients with limited disease can be controlled entirely by it without resorting to systemic therapy²⁵.

The treatment of pemphigus is equally an art and a science. Despite the growing catalog of statistics, pemphigus remains a disease that will not yield to a "cook-book" approach. Instead of a rigid treatment schedule, pemphigus patients require an individualized treatment regimen tailored to the needs of each patient, but of course, administered with a standardized approach.

The results of our therapeutic trial suggest that azathioprine- corticosteroids combination treatment of pemphigus is more effective and safe than corticosteroids alone or betamethasone- cyclophosphamide pulse therapy.

References

1. Singer KH, Hashimoto K, Lazarus GS. Pathophysiology of pemphigus. *Dermatol Clin.* 1983;1 :179-86.
2. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. *Dermatol Clin.* 1993; 11:429-52.
3. Ahmed AR, Moy R. Death in pemphigus. *J. Am. Acad. Dermatol.* 1982;7:221-8.
4. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. *Br.J. Dermatol.* 1979; 101:521-32.
5. Bystryn JC. Adjuvant therapy of pemphigus. *Arch Dermatol.* 1984; 120:941-51.
6. Piamphongsant T, Ophaswongse S. Treatment of pemphigus. *Int.J. Dermatol.* 1991;30:139-46.
7. Pipkin FB. *Medical statistics made easy*. Edinburgh, Churchill Livingstone, 1984, PP. 46-65.
8. Handschumacher RE. Immunosuppressive agents. In: Gihnan AG, Rail IW, Nies AS. et al. eds. *Goodman and Gilman's the pharmacological basis of therapeutics*. Singapore, Pergamon Press. 1991, pp. 1264- 76.
9. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisolone in pemphigus vulgaris: Therapeutic results obtained in 63 patients between 1961 and 1975. *Arch. Dermatol.* 1977;1 13:1236-41.
10. Spark RE. Systemic corticosteroids. In: Fitzpatrick TB, Elsen AZ, Wolff K et al. eds. *Dermatology in general medicine*. New York, McGraw-Hill, 1987, pp. 2564-70.
11. Aki HE, Soho MW, Samparo SA. Postmortem evaluation in endemic pemphigus foliaceus and pemphigus vulgaris. *Med. Cutan. Iber. Lat. Am.* 1984; 12: 15 1-7.
12. Seidenbaum M, David M, Sandbank M. The course and prognosis of pemphigus. A review of 115

patients. *Int. J. Dermatol.*, 1988;27:580-4.

13. Lamey RJ, Rees, TB, Binnie WH et al. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. *Oral Surg. Oral Med. Oral Pathol.*, 1992;74:54-7.
14. Pasricha iS, Ramji G. Pulse therapy with dexamethasone. cyclophosphamide in pemphigus. *Indian J. Dermatol. Venereol, Leproi.*, 1984;50: 199-203.
15. Johnson RB, Lazarus, GS. Pulse therapy: Therapeutic efficacy in the treatment of pyoderma gangrenosum. *Arch. Dermatol.*, 1982,118:76-84.
16. Pasricha iS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. *Br.J. Dermatol.*, 1988;119:73-7.
17. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. *Int.J.. Dermatol.*, 1990;29:371-4.
18. Hietanen J, Salo OP. Pemphigus. An epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. *Acta. Derm. Venereol.*, 1982;62:491 -6.
19. Smorle J, Arazt H. Therapy of pemphigus. Critical remarks passed on 44 clinical cases. *Hautarzt*, 1985;36:96-102.
20. Ratnam Ky, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. *Int. J. Dermatol.*, 1990;29:363-67.
21. Korman NJ. Pemphigus, *Dermatol. Clin.*, 1990,8 :689-700.
22. Peiying J, Changgeng 5, Ganyum YE. Chronic bullous dermatoses in China. *Int.J. Dermatol.*, 1993;32:89-92.
23. Lever WF, Schaumburg LG. Treatment of pemphigus vulgaris: Results obtained in 84 patients between 1961 and 1982. *Arch. Dermatol.*, 1984;10:44-7.
24. Ryan JG. Pemphigus. A 20 years survey of experience with 70 cases. *Arch. Dermatol.*, 1971;104:14-20.
25. Bystryn JC. Therapy of pemphigus. *Semin. Dermatol.*, 1988;7: 186- 94.
26. Korman NJ. Pemphigus. *J. Am. Acad. Dermatol.*, 1988;18:1219-38.